Undisclosed TRIM7 inhibitor / Shattuck - LARVOL DELTA

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "Shattuck Labs,...announced preclinical data demonstrating the therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy. These data were featured in an oral presentation during the AACR Annual Meeting 2024....Shattuck developed a series of small-molecule inhibitors of TRIM7 that specifically disrupt KRAS-mediated tumor cell proliferation, reverse the transcriptional phenotype of PD-1 acquired resistance, and restore sensitivity to anti-PD1 antibodies to PD-1 acquired resistant tumors in pre-clinical models."

Preclinical • Oncology